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Background: Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation
and chronic inflammation. Predicting exacerbations of COPD, which contribute to disease progression, is
important to guide preventative treatment and improve outcomes. Blood eosinophils are a biomarker for
patient responsiveness to inhaled corticosteroids (ICS); however, their effectiveness as a predictive biomarker
for COPD exacerbations is unclear.
Methods: This post hoc analysis pooled data from 11 Boehringer Ingelheim-sponsored Phase III and IV
randomised COPD studies with similar methodologies. Exacerbation data were collected from these studies,
excluding patients from the ICS withdrawal arm of the WISDOM® study. Patients were grouped according to
their baseline blood eosinophil count, baseline ICS use and number of exacerbations in the year prior to each
study.
Results: Exacerbation rate data and baseline eosinophil count were available for 22,125 patients; 45.6%
presented with a baseline blood eosinophil count of ≤ 150 cells/μL, 34.3% with 150–300 cells/μL and 20.1%
with > 300 cells/μL. The lowest exacerbation rates were observed in patients with ≤ 150 cells/μL, with small
increases in exacerbation rate observed with increasing eosinophil count. When stratified by exacerbation
history, the annual rate of exacerbations for patients with 0 exacerbations in the previous year increased
in line with increasing eosinophil counts (0.38 for ≤ 150 cells/μL, 0.39 for 150–300 cells/μL and 0.44 for
> 300 cells/μL respectively). A similar trend was identified for patients with one exacerbation in the previous
year, 0.62, 0.66 and 0.67 respectively. For patients with ≥ 2 exacerbations, exacerbation rates fluctuated
between 1.02 (≤ 150 cells/μL) to 1.10 (150–300 cells/μL) and 1.07 (> 300 cells/μL). Higher exacerbation rates
were noted in patients treated with ICS at baseline (range 0.75 to 0.82 with increasing eosinophil count)
compared with patients not on ICS (range 0.45 to 0.49).
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Conclusion: We found no clinically important relationship between baseline blood eosinophil count and
exacerbation rate. Hence, the current analysis does not support the use of blood eosinophils to predict
exacerbation risk; however, previous exacerbation history was found to be a more reliable predictor of future
exacerbations.
Trial registration: ClinicalTrials.gov Identifiers: NCT00168844, NCT00168831, NCT00387088, NCT00782210,
NCT00782509, NCT00793624, NCT00796653, NCT01431274, NCT01431287, NCT02296138 and NCT00975195.
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People with chronic obstructive pulmonary disease often
start treatment with either a long-acting muscarinic antag-
onist or a long-acting β2-agonist. Doctors can prescribe
these treatments together (long-acting muscarinic antag-
onist/long-acting β2-agonist) if needed. Other medicines
called inhaled corticosteroids can be added as required.
Measuring the number of eosinophils, a type of white
blood cell, in the blood can help to predict which people
will benefit most from inhaled corticosteroid treatment.
People with chronic obstructive pulmonary disease
sometimes experience a worsening of their symptoms,
known as an exacerbation. Eosinophil levels may be useful
to predict the risk of exacerbations. We studied the results
from 11 clinical trials, involving 22,125 people with
chronic obstructive pulmonary disease. We looked at how
many exacerbations people had during these trials and
whether this was linked to the level of eosinophils in their
blood, their previous history of exacerbations, or whether
they had been treated with inhaled corticosteroids before.
Overall, we found that a previous history of exacerba-
tions predicted the future rate of exacerbations. We did
not find a clear link between the rate of exacerbations
and eosinophil levels.Background
Characterised by progressive airflow limitation and
chronic inflammation, chronic obstructive pulmonary
disease (COPD) is a major source of morbidity and mor-
tality that mainly affects individuals above the age of 35
years [1, 2]. COPD exacerbations, defined as acute wors-
ening of respiratory symptoms requiring a change in
treatment [3], are important events that contribute to
disease progression. In particular, severe exacerbations
(defined as events requiring hospitalisation) are associ-
ated with a significantly worse survival and reduced
quality of life [3]. The Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) strategy report recom-
mends that inhaled corticosteroids (ICS), used in
combination with long-acting bronchodilator(s), are a
useful treatment for patients with a history of exacerba-
tions [4, 5]. GOLD also supports the use of blood eo-
sinophil counts as a biomarker in clinical practice topredict the likelihood of ICS benefit in terms of prevent-
ing future exacerbations [4].
Predicting exacerbations is important for clinicians
treating patients with COPD and for designing clinical
trials. At present, the strongest predictor of future
COPD exacerbations is the past history of moderate and
severe exacerbations [4, 6]. Exacerbation risk is also as-
sociated with an increase in symptom severity and worse
lung function [7]. Additionally, characteristics such as
female sex, older age, lower forced expiratory volume in
1 s (FEV1) and persistent cough have been shown to be
predictive of higher exacerbation rates [7, 8]. However,
while a number of biomarkers have been studied to pre-
dict exacerbations in COPD [3, 9–11], none are cur-
rently used in clinical practice.
Randomised controlled trials (RCTs) in COPD patients
have shown that blood eosinophil counts predict the re-
sponse to ICS [12, 13]. Consequently, blood eosinophil
counts have utility in clinical practice to direct ICS use
in COPD patients, and as a biomarker in clinical trials to
identify subgroups with different responses to anti-
inflammatory drugs [14]. However, publications investi-
gating the relationship between blood eosinophils and
exacerbation risk have produced conflicting results [15–
19]. Some observational cohort studies have reported
that higher eosinophil levels are associated with future
COPD exacerbations [15–17], but other studies suggest
that there is no relationship [18, 19].
RCTs of ICS-containing combination treatments in
patients with a history of exacerbations have consistently
reported that there is no increase in exacerbation rates
at higher blood eosinophil counts in patients allocated
to receive ICS treatment, while increased exacerbation
rates are observed at higher blood eosinophil counts in
patients allocated to receive bronchodilator treatment
without ICS [20–22]. This suggests that the use of ICS
obscures any relationship between blood eosinophil
counts and exacerbation rates.
Another key factor that affects the relationship be-
tween eosinophil levels and future exacerbations is the
degree of study population enrichment with patients at
increased risk of future exacerbations. Previous RCTs of
ICS-containing combination treatments demonstrating a
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acerbation rates (in patients randomised to non-ICS
treatment) have included patients with a history of exac-
erbations in the previous year [20]. Furthermore, analysis
of the ECLIPSE and COPDgene studies showed that the
relationship between exacerbation risk and eosinophil
count was clearest in patients with ≥ 2 exacerbations in
the last year [17].
The aim of the present analysis was to further investi-
gate whether blood eosinophil counts predict future rate
of exacerbations by pooling data from a large number of
clinical trials. These included patients with COPD who
experienced exacerbations at different frequencies and of
varying severity. Patients were stratified by recognised
eosinophil cut-off levels at baseline [23, 24] and the rate
of exacerbations was compared between eosinophil sub-
groups. Exacerbation rates for different eosinophil sub-
groups were assessed according to exacerbation history
and ICS use at baseline.Methods
Study design
Data from 11 previously published clinical studies were
pooled in the current analysis [25–32]. These studies were a
collection of Phase III and IV multicentre, double-blindRCTs
where patients were treated with tiotropium, olodaterol or
tiotropium/olodaterol combination therapy (ClinicalTrials.gov:
NCT00168844, NCT00168831, NCT00387088, NCT00782210,
NCT00782509, NCT00793624, NCT00796653, NCT01431274,
NCT01431287, NCT02296138), as well as the WISDOM® ICS
withdrawal study (NCT00975195). The inclusion and
exclusion criteria have been described in detail
previously [25–32]. Briefly, patients were included if
they were aged ≥ 40 years with a diagnosis of COPD,
had a smoking history of > 10 pack-years, a post-
bronchodilator FEV1 of < 80% predicted (or < 60%) [26]
and a post-bronchodilator FEV1/forced vital capacity of
< 70%. All studies excluded patients with a confirmed
diagnosis of asthma. All studies were conducted in
accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines.
The current analysis focuses on patients with COPD
who had documented eosinophil counts at baseline.
Studies were included if they recorded exacerbations
through the entire study period. The withdrawal arm of
the WISDOM trial [31] was excluded from the analysis
to avoid including patients with mandated ICS with-
drawal. Patients on ICS at baseline continued ICS use
during their respective trials.Statistical analysis
This post hoc analysis investigated the association
between different blood eosinophil count categories(≤ 150 cells/μL, > 150–≤ 300 cells/μL and > 300 cells/μL)
and the annual rate of moderate-to-severe exacerbations.
Data from patients across all studies were pooled
and exacerbation rate data were analysed according
to patients’ baseline eosinophil count (≤ 150 cells/μL,
> 150–≤ 300 cells/μL or > 300 cells/μL), exacerbation
history (stratified as either ‘infrequent exacerbators’
[≤ 1 moderate exacerbation and no severe exacerba-
tions in the previous year] or ‘frequent exacerbators’
[≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in
the previous year]), and ICS use at baseline or according
to both ICS use at baseline and exacerbation history.
COPD exacerbations were counted from the start to the
end of treatment. Patients were followed for the duration
of each clinical trial (a minimum of 48 weeks).
Annual rates of exacerbations were assessed using nega-
tive binomial models with treatment exposure as offset, ad-
justed for treatment, study, ICS use at baseline, region,
GOLD stage, smoking status, baseline eosinophil count,
and number of exacerbations in previous year as covariates.
Results
Patient demographics
From the pooled population, baseline eosinophil data were
collected from 22,125 patients who also had exacerbation
rate data (Fig. 1). The proportion of patients within each
eosinophil subgroup was similar, irrespective of ICS use at
baseline or exacerbation history (Fig. 2a and b). At base-
line, the eosinophil count was ≤ 150 cells/μL in 10,096 pa-
tients (45.6%), > 150–≤ 300 cells/μL in 7581 patients
(34.3%) and > 300 cells/μL in 4448 patients (20.1%). Me-
dian eosinophil count at baseline was 170.0 cells/μL.
Baseline characteristics are shown in Table 1. Mean
age, gender split, smoking status, number of pack-years
and incidence of moderate-to-severe exacerbations in
the previous year were comparable between the three
eosinophil subgroups. The majority of patients (74.1%)
were male; 63.2% were ex-smokers and 36.8% were
current smokers.
Exacerbation rate by eosinophil count and exacerbation
history
In the total patient population, prospective annual ex-
acerbation rates observed during the studies were nu-
merically similar across the three eosinophil subgroups
(≤ 150 cells/μL, 150–300 cells/μL and > 300 cells/μL;
range: 0.62–0.67). When compared with patients with a
baseline eosinophil count of ≤ 150 cells/μL, patients in
the > 150–≤ 300 cells/μL and > 300 cells/μL subgroups
had exacerbation rate ratios (RRs) of 1.05 (95% confi-
dence interval [CI] 1.00, 1.11) and 1.09 (95% CI 1.03,
1.15), respectively (Table 2).
In patients with ≤ 1 exacerbation in the previous year,
annual exacerbation rates ranged from 0.51 to 0.57
Fig. 1 Baseline blood eosinophil levels in the total population. Baseline blood eosinophil count from 22,125 patients with accompanying
exacerbation data
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line eosinophil count of ≤ 150 cells/μL, patients in the
> 150–≤ 300 cells/μL and > 300 cells/μL subgroups had
exacerbation RRs of 1.04 (95% CI 0.98, 1.11) and 1.10
(95% CI 1.03, 1.19), respectively. As shown in Table 2,
similar patterns were identified in patients with 0 or
1 exacerbation in the previous year.
In patients with ≥ 2 exacerbations in the previous year,
annual exacerbation rates ranged from 1.02 to 1.10
(Table 2). When compared with patients with a base-
line eosinophil count of ≤ 150 cells/μL, patients in the
> 150–≤ 300 cells/μL and > 300 cells/μL subgroups had
RRs of 1.08 (95% CI 0.99, 1.16) and 1.04 (95% CI
0.95, 1.15), respectively.
Exacerbation rate in patients stratified by ICS use at
baseline
In the pooled analysis, 13,295 patients were receiving
ICS at baseline; 8830 patients were not receiving ICS at
baseline. Higher annual exacerbation rates were ob-
served in patients receiving ICS at baseline (range 0.75
to 0.82 exacerbations) compared with non-ICS users
(range 0.45 to 0.49) (Fig. 2b, Table 3).
For patients on ICS at baseline, when compared with the
≤ 150 cells/μL group, patients in the > 150–≤ 300 cells/μL
and > 300 cells/μL subgroups had exacerbation RRs of
1.05 (95% CI 0.99, 1.11) and 1.09 (95% CI 1.02, 1.17),
respectively. For non-ICS patients, when compared with the
≤ 150 cells/μL group, patients in the > 150–≤ 300 cells/μLand > 300 cells/μL subgroups had exacerbation RRs of 1.07
(95% CI 0.97, 1.17) and 1.09 (95% CI 0.98, 1.21), respectively
(Table 3).
Exacerbation rate in patients stratified by exacerbation
history before study start and ICS use at baseline
Table 4 shows the annual exacerbation rates stratified by
exacerbation history and ICS use at baseline. For non-
ICS patients with ≤ 1 exacerbation in the previous year,
patients in the > 150–≤ 300 cells/μL and > 300 cells/μL
subgroups had exacerbation RRs of 1.08 (95% CI
0.97, 1.20) and 1.14 (95% CI 1.00, 1.29), respectively,
when compared with the ≤ 150 cells/μL group; pa-
tients with ≥ 2 exacerbations in the previous year in the
> 150–300 cells/μL and > 300 cells/μL subgroups had
exacerbation RRs of 1.04 (95% CI 0.88, 1.23) and 0.97
(95% CI 0.79, 1.19), respectively.
In patients treated with ICS at baseline, we identified
higher annual exacerbation rates for each of these
analyses compared with their non-ICS equivalents
(Table 4). For ICS patients with ≤ 1 exacerbation in
the previous year, patients in the > 150–≤ 300 cells/μL
and > 300 cells/μL subgroups had exacerbation RRs of
1.02 (95% CI 0.95, 1.10) and 1.10 (95% CI 1.00, 1.19),
respectively, when compared with the ≤ 150 cells/μL
group; patients with ≥ 2 exacerbations in the previous
year in the > 150–300 cells/μL and > 300 cells/μL sub-
groups had exacerbation RRs of 1.09 (95% CI 1.00, 1.19)
and 1.07 (95% CI 0.96, 1.19), respectively.
Fig. 2 a Eosinophil count at baseline by exacerbation history. b Eosinophil count at baseline by ICS use. ICS, inhaled corticosteroids
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In this analysis, which focuses on the value of blood eo-
sinophil counts as a biomarker for future exacerbations,
we did not find a strong association between blood eo-
sinophil counts and annual exacerbation rates during
the study period; this was true regardless of exacerbation
history or ICS use. There was a pattern across the ma-
jority of the subgroups analysed, demonstrating that the
lowest exacerbation rates were observed in patients with
≤ 150 cells/μL. However, the increases in exacerbation
rate observed with increasing eosinophil count were
small, with RRs between 0.97 and 1.17.
In line with previous studies, ICS users experienced a
higher rate of exacerbations compared with non-ICS users,most likely due to bias by indication, because these patients
were receiving ICS as a result of previous exacerbation
events [12]. Similarly, patients with a history of ≥ 2 exacer-
bations in the previous year also experienced a higher rate
of exacerbations (range 1.02–1.10) during the study period
than patients with ≤ 1 exacerbation in the previous year
(range 0.51–0.57). This is consistent with previous studies
reporting that the best predictor of future exacerbation risk
is the patient’s exacerbation history [23]. Overall, using
exacerbation history or ICS use as stratification factors
resulted in an increase in the observed exacerbation rate.
We observed over 100% increase in exacerbation rate in pa-
tients with ≥ 2 exacerbations in the previous year compared
with patients with no exacerbations in the previous year. In
Table 1 Baseline patient characteristics
Characteristic ≤ 150 cells/μL
(n = 10,096)
> 150–≤ 300 cells/μL
(n = 7581)
> 300 cells/μL
(n = 4448)
Total
(N = 22,125)
Male, n (%) 7120 (70.5) 5694 (75.1) 3584 (80.6) 16,398 (74.1)
Mean age, years (SD) 65.3 (8.6) 65.0 (8.6) 64.6 (8.7) 65.1 (8.6)
Smoking status, n (%)
Never smoked 0 (0.0) 0 (0.0) 1 (0.0) 1 (0.0)
Ex-smoker 6299 (62.4) 4788 (63.2) 2897 (65.1) 13,984 (63.2)
Current smoker 3797 (37.6) 2793 (36.8) 1550 (34.8) 8140 (36.8)
Smoking history, mean pack-years (SD) 45.6 (26.0) 45.7 (25.3) 45.0 (25.7) 45.5 (25.7)
Moderate-to-severe exacerbations in previous year, n (%)
0 2850 (28.2) 2416 (31.9) 1347 (30.3) 6613 (29.9)
1 4672 (46.3) 3229 (42.6) 1907 (42.9) 9808 (44.3)
2 1565 (15.5) 1195 (15.8) 709 (15.9) 3469 (15.7)
3 533 (5.3) 385 (5.1) 251 (5.6) 1169 (5.3)
4 220 (2.2) 145 (1.9) 107 (2.4) 472 (2.1)
> 4 256 (2.5) 211 (2.8) 127 (2.9) 594 (2.7)
Severe exacerbations in previous year, n (%)
0 8265 (81.9) 6362 (83.9) 3683 (82.8) 18,310 (82.8)
1 1501 (14.9) 970 (12.8) 614 (13.8) 3085 (13.9)
2 258 (2.6) 198 (2.6) 115 (2.6) 571 (2.6)
3 44 (0.4) 31 (0.4) 19 (0.4) 94 (0.4)
4 19 (0.2) 12 (0.2) 8 (0.2) 39 (0.2)
> 4 9 (0.1) 8 (0.1) 9 (0.2) 26 (0.1)
Mean pre-bronchodilator FEV1 at screening; L (SD) 1.15 (0.45) 1.18 (0.46) 1.16 (0.46) 1.16 (0.46)
ICS use at baseline, n (%) 6149 (60.9) 4477 (59.1) 2669 (60.0) 13,295 (60.1)
FEV1 Forced expiratory volume in 1 s; ICS Inhaled corticosteroids; SD Standard deviation.
Table 2 Rate ratio of annual exacerbation rates according to exacerbation history by baseline eosinophil count (cells/μL)
≤ 150 cells/μL > 150–≤ 300 cells/μL > 300 cells/μL
All All patients n = 22,125 Rate: 0.62 Rate: 0.65
RR: 1.05
(95% CI 1.00, 1.11)
Rate: 0.67
RR: 1.09
(95% CI 1.03, 1.15)
Exacerbation history 0 exacerbations n = 6792 Rate: 0.38 Rate: 0.39
RR: 1.01
(95% CI 0.90, 1.12)
Rate: 0.44
RR: 1.14
(95% CI 1.00, 1.30)
1 exacerbation n = 9759 Rate: 0.62 Rate: 0.66
RR: 1.07
(95% CI 0.99, 1.15)
Rate: 0.67
RR: 1.10
(95% CI 1.01, 1.19)
≤ 1 exacerbation n = 16,551 Rate: 0.51 Rate: 0.53
RR: 1.04
(95% CI 0.98, 1.11)
Rate: 0.57
RR: 1.10
(95% CI 1.03, 1.19)
≥ 2 exacerbations n = 5574 Rate: 1.02 Rate: 1.10
RR: 1.08
(95% CI 0.99, 1.16)
Rate: 1.07
RR: 1.04
(95% CI 0.95, 1.15)
RR versus ≤ 150 cells/μL eosinophil subgroup.
CI Confidence interval; RR Rate ratio.
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Table 3 Rate ratio of annual exacerbations according to ICS use by baseline eosinophil count (cells/μL)
≤ 150 cells/μL > 150–≤ 300 cells/μL > 300 cells/μL
Baseline ICS use No n = 8830 Rate: 0.45 Rate: 0.48
RR: 1.07
(95% CI 0.97, 1.17)
Rate: 0.49
RR: 1.09
(95% CI 0.98, 1.21)
Yes n = 13,295 Rate: 0.75 Rate: 0.79
RR: 1.05
(95% CI 0.99, 1.11)
Rate: 0.82
RR: 1.09
(95% CI 1.02, 1.17)
RR versus ≤ 150 cells/μL eosinophil subgroup.
CI Confidence interval; ICS Inhaled corticosteroids; RR Rate ratio.
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paring the lowest eosinophil count with the higher eosino-
phil counts.
Several analyses of data from RCTs have investigated the
relationship between blood eosinophils and ICS use, and
have shown that blood eosinophil count correlates with
clinical response to ICS with regards to reducing exacerba-
tion rates [20, 33–35]. These study designs include ICS
withdrawal for many patients, where treatment differences
become apparent at higher blood eosinophil counts; an as-
sociation between exacerbation rates and blood eosinophil
counts can then be more clearly observed in patients not
receiving ICS. In the current analysis, none of the 11 indi-
vidual studies, and by extension the pooled analysis, were
designed to study the relationship between blood eosino-
phils as a predictor of response to ICS in patients experien-
cing exacerbations, and therefore this topic is beyond the
scope of the current manuscript. In the pooled population,Table 4 Rate ratio of annual exacerbations combining ICS use and e
Exacerbation history and ICS use 0 exacerbations and no ICS n = 3784
0 exacerbations and ICS n = 3008
1 exacerbation and no ICS n = 3378
1 exacerbation and ICS n = 6381
≤ 1 exacerbation and no ICS n = 7162
≤ 1 exacerbation and ICS n = 9389
≥ 2 exacerbations and no ICS n = 166
≥ 2 exacerbations and ICS n = 3906
RR versus ≤ 150 cells/μL eosinophil subgroup.
CI Confidence interval; ICS Inhaled corticosteroids; RR Rate ratio.which included patients with stable ICS use or non-use, we
did not find a strong association between blood eosinophil
counts and annual exacerbation rates.
Some cohort studies have also shown an association
between blood eosinophil counts and exacerbation risk.
Vedel-Krogh et al. found that individuals with a blood
eosinophil count above 340 cells/μL had a higher risk of
severe exacerbations compared with patients below this
value (odds ratio 1.76; 95% CI 1.56, 1.99) [15]. In
addition, Yun et al. found that patients with blood eo-
sinophil counts ≥ 300 cells/μL had an increased risk of
exacerbations in the COPDGene study [17]. However, a
retrospective study of 992 patients with COPD by Adir
et al. found that, among patients who experienced severe
exacerbations (72%) and those that did not (71%), there
was no difference in the proportion of patients with
eosinophil counts of ≥ 2% (P = 0.93) [18]. Similarly, a
recent population-based study in 57,209 patients withxacerbation history by eosinophil count (cells/μL)
≤ 150 cells/μL > 150–≤ 300 cells/μL > 300 cells/μL
Rate: 0.31 Rate: 0.31
RR: 1.03
(95% CI 0.87, 1.21)
Rate: 0.36
RR: 1.17
(95% CI 0.97, 1.40)
Rate: 0.49 Rate: 0.49
RR: 1.00
(95% CI 0.86, 1.16)
Rate: 0.55
RR: 1.12
(95% CI 0.94, 1.33)
Rate: 0.48 Rate: 0.55
RR: 1.15
(95% CI 1.00, 1.32)
Rate: 0.52
RR: 1.09
(95% CI 0.91, 1.29)
Rate: 0.69 Rate: 0.72
RR: 1.04
(95% CI 0.95, 1.13)
Rate: 0.76
RR: 1.10
(95% CI 1.00, 1.22)
Rate: 0.39 Rate: 0.42
RR: 1.08
(95% CI 0.97, 1.20)
Rate: 0.44
RR: 1.14
(95% CI 1.00, 1.29)
Rate: 0.62 Rate: 0.64
RR: 1.02
(95% CI 0.95, 1.10)
Rate: 0.68
RR: 1.10
(95% CI 1.00, 1.19)
8 Rate: 0.79 Rate: 0.82
RR: 1.04
(95% CI 0.88, 1.23)
Rate: 0.76
RR: 0.97
(95% CI 0.79, 1.19)
Rate: 1.13 Rate: 1.24
RR: 1.09
(95% CI 1.00, 1.19)
Rate: 1.21
RR: 1.07
(95% CI 0.96, 1.19)
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eosinophil count and risk of exacerbations [19].
As eosinophil levels are known to vary over time, this
may lead to patients fluctuating between different eosino-
phil categories, despite the patient experiencing only a
small absolute change [36, 37]. This may, at least in part,
explain why the relationship is difficult to conclude.
When assessing eosinophils in categories, the current
study did not show a strong relationship between blood
eosinophil counts and risk of future exacerbations. Al-
though there is a paucity of data evaluating blood eo-
sinophil count as a continuous value, Bafadhel et al. [20]
modelled eosinophil count as a continuous variable and
showed an increase in exacerbation rate in line with in-
creasing eosinophil count in patients not receiving ICS.
In clinical practice, eosinophils alone should not be used
as a predictor of exacerbation risk, but as a potential
biomarker of response to ICS in patients with increased
exacerbation risk [20, 33–35].
Other candidate biomarkers have been studied as pre-
dictors of increased risk of COPD exacerbations [3, 9–
11], including bone morphogenic protein-3, Cerberus 1,
inhibin B, thrombopoietin, matrix metalloproteinase-10
and a number of interleukin family members [11]. In pa-
tients with stable COPD, elevated levels of fibrinogen
have been associated with an increased risk of frequent
exacerbations [9, 38].
In RCTs, blood eosinophil counts > 300 cells/μL are
associated with the greatest effect of ICS on exacerbation
prevention. In this analysis, 20.1% had eosinophil counts
above this threshold. These results are in line with other
studies that suggest that around 25% of patients have eo-
sinophil counts higher than 300 cells/μL [12, 19, 39].
Our analysis has some advantages. Since the pooled
studies were all conducted by one pharmaceutical com-
pany (Boehringer Ingelheim), the methodologies be-
tween these studies are generally compatible. Due to the
pooled population, this analysis has a very large sample
size and is sufficiently powered to detect even modest
changes in exacerbation frequency. However, similar to
observational studies, post hoc analyses should be
treated with caution as these may be subject to bias. Sec-
ondly, the inclusion and exclusion criteria between the
studies are mostly generalisable; however, additional fac-
tors such as comorbidities may be present in some of
the pooled patient population, which were not con-
trolled for and may introduce variability. Thirdly, the
pooled studies included a number of active-controlled,
or placebo-controlled studies. In COPD, active-
controlled studies compare the drug of interest against a
leading comparator in the field. Although more ethical,
the results of the active-controlled trials could impact on
the overall exacerbation rates. It is important to note
that this pooled analysis was not designed to assess arelationship between blood eosinophil count and re-
sponse to ICS use. The scope of this study was to deter-
mine the use of eosinophils as a predictor of
exacerbations.
What are the practical implications of our study? For
many of the currently studied biomarkers of exacerba-
tion risk, the data are conflicting [40]. Whilst blood eo-
sinophils are recommended as a predictor of likely
response to ICS, the results from this pooled analysis in-
dicate that eosinophil levels cannot be confidently used
as a predictive marker for rate of future COPD exacerba-
tions, as we were unable to identify a strong relationship
between the rate of exacerbations and eosinophil levels.
In the absence of a clear biomarker to predict the risk of
future exacerbations among patients with COPD, previ-
ous history of exacerbations continues to be the stron-
gest predictor of future exacerbation risk [17].
Conclusions
In this pooled analysis of 22,125 patients with COPD, we
did not find a clinically important relationship between
baseline blood eosinophil count and exacerbation rate. This
analysis, coupled with other studies on this topic [18, 19],
indicate that blood eosinophil counts are not a clinically
useful predictor of future exacerbation risk.
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